BioGaia AB   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Stockholm Sweden (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2001
NCT01285830
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioGaia AB | BioGaia AB, Sweden | BioGaia Pharma | BioGaia Pharma AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdominal Pain (Phase 4)

Anorexia (Phase 3)

Anorexia Nervosa (Phase 3)

Birth Weight (Phase 2)

Bone Diseases, Metabolic (Phase 2)

Chronic Periodontitis (Phase 4)

Constipation (Phase 3)

Diarrhea (Phase 3)

Dysbiosis (Phase 4)

Dyspepsia (Phase 3)

Enterocolitis (Phase 2)

Enterocolitis, Necrotizing (Phase 2)

Failure to Thrive (Phase 2)

Gastroenteritis (Phase 3)

Halitosis (Phase 4)

Periodontitis (Phase 4)

Premature Birth (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 47
  • # of Trial APIs: 14